$90.89
-0.033%Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Chief Operating Officer
Compensation
$1,076,905
Director of Investor Relations
Executive Vice President & Chief Financial Officer
Compensation
$872,860
Executive Vice President & Chief Human Resources Officer
Compensation
$791,644
Executive Vice President of Global Operations & Manufacturing Strategy
Compensation
$822,685
President of Cardiac Rhythm Management & Neuromodulation
Compensation
$890,704
President of Cardio & Vascular
President, Chief Executive Officer & Director
Compensation
$3,175,447
Senior Vice President, General Counsel, Chief Ethics & Compliance Officer and Corporate Secretary
Vice President, Corporate Controller & Principal Accounting Officer
During the last 12 months, insiders have purchased $500K and sold $132K worth of ITGR shares, resulting in $368K of net buying activity.
0
0.00
825
70.12K
-70K
-$70K
0
0.00
0
0.00
+0
+$0
7.5K
500.20K
884
62.01K
+438K
+$438K
0
0.00
0
0.00
+0
+$0
Khales Payman
Director, Officer: President & Ceo
$203K
Harris John A
Officer: Evp, Global Ops And Manufactur
$116K
Capps Cheryl C
Director
$107K
Smith Diron
Officer: Evp, Chief Financial Officer
$75K
Thomas Tommy P
Officer: Vp, Corporate Controller
$132K
Strong bullish signal with $368K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
ITGR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 07, 2025 | April 07, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 08, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 10, 2023 | April 10, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 04, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 05, 2021 | May 19, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 15, 2020 | May 20, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 12, 2019 | May 22, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 18, 2018 | May 22, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 17, 2017 | May 23, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.